Rate Video

ASH 2015 | Overview of RESONATE-2 clinical trial of ibrutinib in CLL

John Gribben and Stephan Stilgenbauer • 4 Dec 2015

ASH 2015

Chronic Lymphocytic Leukemia Ibrutinib

RESONATE-2

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).

Exciting new agents in CLL

John Gribben • 9 Jun 2022

Venetoclax resistance and alternative treatments in CLL

John Gribben • 8 Dec 2017

iwNHL 2015 roundtable: Day 2 highlights – ibrutinib for diffuse large B-cell lymphoma

John Gribben et al. • 3 Oct 2015

Financial benefit of combining two expensive drugs for CLL

John Gribben • 8 Dec 2017

CLL2-GIVe trial: investigating chemotherapy-free treatment of CLL

Stephan Stilgenbauer • 17 Sep 2016

Chemo-free regimens continue for CLL

Stephan Stilgenbauer • 7 Dec 2019

iwCLL – International Workshop on Chronic Lymphocytic Leukemia

Federico Caligaris-Cappio et al.

The role of transplant in CLL and Richter's transformation today

Stephan Stilgenbauer • 16 Sep 2016

Related Videos

Venetoclax plus obinutuzumab in CKT CLL: analysis from the CLL14 trial

Othman Al-Sawaf

Impressive results from phase 3 RESONATE trial in CLL

Challenges after CAR T-cell therapy

Novel agents in CLL: acalabrutinib and zanubrutinib

Barbara Eichhorst